Lys Therapeutics
Develops monoclonal antibody LYS241 targeting neurovascular pathways for Parkinson's disease and stroke
>€25MSeed
Role not disclosedLoading investors…
Activity from announced rounds
Develops monoclonal antibody LYS241 targeting neurovascular pathways for Parkinson's disease and stroke